Yang He

Yang He


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
PLPanpan Luo
Panpan Luo
YGYuge Guo
Yuge Guo
YHYang He
Yang He
CWChunjiang Wang
Chunjiang Wang

15 October 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
CWChunjiang Wang
Chunjiang Wang
YHYang He
Yang He
WSWei Sun
Wei Sun
CWCuifang Wu
Cuifang Wu
ZLZuojun Li
Zuojun Li
LSLinli Sun
Linli Sun

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
TWTian Wu
Tian Wu
YHYang He
Yang He
ZFZhiqiang Fan
Zhiqiang Fan
WSWei Sun
Wei Sun
ZLZuojun Li
Zuojun Li
CWChunjiang Wang
Chunjiang Wang
Background. Acute generalized exanthematous pustulosis (AGEP) is a rare and serious adverse reaction of terbinafine. Understanding AGEP and terbinafine is primarily based on case reports. The purpose is to explore the clinical characteristics of terbinafine‐induced AGEP, and to provide reference for clinical diagnosis and treatment. Methods. Case reports and original studies of terbinafine‐induced AGEP were retrieved by searching Chinese and English databases from January, 1991, to May 31, 2022. Results. The median age of the 32 patients (17 males and 15 females) was 55 years (range: 6–84). The median time to onset of AGEP is 8 days (range: 1–77) and is usually accompanied by fever (>38°C) and elevated neutrophil levels (>8000/mm3). Four patients (12.5%) had oral mucosal involvement, and 10 patients (31.3%) developed postpustular desquamation. The lesions were mainly distributed in the trunk (43.8%), the whole body (34.4%), and the extremities (53.1%). Skin biopsy revealed subcorneal pustules (65.6%), intraepidermal cavernous pustules (43.8%), necrotic keratinocytes (15.6%), spongy hyperplasia (25.0%), neutrophil exocytosis (34.4%), and papillary dermal edema (40.6%). AGEP resolved completely in all patients at a median time of 12 days (range: 2–90) after discontinuation of terbinafine and symptomatic therapy. Conclusion. Clinicians should be aware that terbinafine‐induced AGEP is a rare cutaneous adverse reaction. AGEP usually occurs within 2 weeks after administration and has a good prognosis after discontinuation.

13 January 2024 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
HLHaibo Lei
Haibo Lei
ZFZhiqiang Fan
Zhiqiang Fan
YHYang He
Yang He
WSWei Sun
Wei Sun
ZLZuojun Li
Zuojun Li
CWChunjiang Wang
Chunjiang Wang
Background. Amoxicillin was associated with acute generalized exanthematous pustulosis (AGEP), and the clinical characteristics were not clear. The purpose of this study was to explore the clinical characteristics of amoxicillin‐induced AGEP and to provide a basis for prevention and treatment. Methods. Case reports and case series of amoxicillin‐induced AGEP were collected for retrospective analysis by searching the Chinese and English databases from inception to January 31, 2023. Results. A total of 46 patients were included with a median age of 40 years (range 1.4, 87). The onset time of AGEP ranged from 6 hours to 28 days, with a median of 2.5 days. Fever occurred in 32 patients (69.6%), and pruritus occurred in 13 patients (28.3%). Ten patients (21.7%) had mucous membrane involvement and systemic involvement, respectively. Twenty‐two patients had elevated neutrophils, with a median of 12850/mm3 (range 7880, 29140). Skin biopsy mainly showed subcorneal pustules (22 cases, 47.8%), spongy pustules (14 cases, 30.4%), and inflammatory cell infiltration (26 cases, 56.5%). Skin lesions disappeared in a median of 10 days (range 2, 42) after discontinuation of amoxicillin and administration of topical steroids (26 cases, 56.5%) as well as systemic corticosteroids (13 cases, 28.3%). Conclusions. AGEP is a rare complication of amoxicillin and is self‐limiting. Clinicians should correctly identify AGEP and should avoid represcribing amoxicillin. Clinicians should correctly identify AGEP and avoid represcribing amoxicillin, which can prevent unnecessary treatment measures.